Medulloblastoma

Rady Children's Appoints Praveen Raju, MD, PhD, as the Nathan Gordon Chair and Medical Director of Neuro-Oncology Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Diagnosis, Boston Children's Hospital, Brain, Health, Growth, Neurology, MSTP, Memory, Genetics, SAN, Patient, UC, Cancer, Medulloblastoma, Child, University, Neurosurgery, Doctor of Philosophy, Neuro, MD, Molecular biology, NIH, Laboratory, Pediatric neurosurgery, Neoplasm, Infant, Nathan Gordon, Hospital, Spinal cord, Pediatrics, Neuro-Oncology (journal), Medical director, Genetic distance, Nursing

At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.

Key Points: 
  • At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.
  • As part of Rady Children's nationally recognized care team, Dr. Raju will spearhead the growth of the Neuro-Oncology Program and advance research efforts on pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise, Dr. Raju aims to address different forms of pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise into the Neuro-Oncology Program, Dr. Raju aims to address the different forms and distinct molecular subtypes of pediatric brain and spinal tumors.

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 29, 2024
Incidence, Osteosarcoma, Fennec, FDA, TSX, Food, Neuroblastoma, Germ cell tumor, Hepatoblastoma, Risk, Literacy, Safety, Audit, Cisplatin, Hearing loss, Medulloblastoma, Kool-Aid, Ototoxicity, Food and Drug Administration, Patient, Survival, FENC, COG

RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.

Key Points: 
  • ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~
    RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.
  • The information in this press release is based upon preliminary unaudited information and management estimates for the fourth quarter 2023 and is subject to the completion of Fennec’s financial closing procedures and year end audit.
  • Preliminary Unaudited 2023 Fourth Quarter Revenue and Year End Performance:
    Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.
  • Fennec expects to report its 2023 fourth quarter and audited full-year year results of operations on or about March 26, 2024.

International Team Led by CHOP Cancer Expert Receives Multimillion Dollar Grant for Childhood Cancer Research from Cancer Grand Challenges

Retrieved on: 
Wednesday, March 6, 2024
Survivor, Oncogene, Ewing sarcoma, Doctor of Philosophy, Neoplasm, Cancer Research UK, Hospital, Neuroblastoma, Child, National Cancer Institute, Medulloblastoma, University, Therapy, KiKa, Protein, CHOP, Survival, Pediatrics, Team, Fibrolamellar hepatocellular carcinoma, Rhabdomyosarcoma, Partnership, Pharmaceutical industry

PHILADELPHIA, March 6, 2024 /PRNewswire/ -- An interdisciplinary, global team of scientists led by Yael Mossé, MD, Professor of Pediatrics in the Cancer Center at Children's Hospital of Philadelphia (CHOP), has been selected as one of five research teams from all over the world to receive funds from Cancer Grand Challenges, a funding initiative co-founded by the National Cancer Institute and Cancer Research UK. Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.

Key Points: 
  • Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.
  • Last year, 176 global teams submitted bold ideas for tackling some of the most pressing challenges in cancer research and care.
  • The National Cancer Institute and Cancer Research UK, the world's leading funders of cancer research, co-founded and launched the Cancer Grand Challenges initiative in 2020.
  • In addition to the Team KOODAC3 award, Team MATCHMAKERS, which includes Dr. Nikolaos G. Sgourakis from CHOP, also received a Cancer Grand Challenges award of up to $25 million.

Proton beam therapy: A modern treatment for cancer, but not in Canada (yet)

Retrieved on: 
Tuesday, February 6, 2024
Proton, Partnership, Meal, Proton therapy, Travel, Pelvis, Deficit spending, Prostate, Patient, G7, Brain, Spine, Medulloblastoma, McGill University Health Centre, Tissue, Cancer, Abdomen, Ability, Disease, Medical imaging

Proton beam therapy is a more precise treatment that can better focus radiation on a cancer, reducing the side-effects of treatment.

Key Points: 
  • Proton beam therapy is a more precise treatment that can better focus radiation on a cancer, reducing the side-effects of treatment.
  • This leads to better cognitive function and fewer long-term side-effects among patients who receive proton therapy compared to X-ray (photon) treatment.
  • Although proton therapy is more expensive to deliver than photon radiation, studies have shown long-term cost-effectiveness of proton beam therapy for medulloblastoma.
  • In a study of more than 1,000 adults with other types of locally advanced cancer, proton therapy led to fewer unplanned hospitalizations.

Canadian patients need to travel for treatment

  • Researchers in the U.K. estimate that up to 15 per cent of all patients with curable cancers may benefit from proton therapy.
  • However, without a domestic facility, Canadians who need proton beam therapy must travel out-of-country to receive this medically necessary treatment for their cancer.


Patients who are able to travel out-of-country report high levels of stress and feelings of isolation. Many of these concerns would be reduced with a domestic, Canadian proton therapy facility.

Progress toward Canadian facilities


In 2016, Québec announced a partnership with a private health-care company to build a standalone proton therapy facility in Montréal.

  • It is recognized that the per-patient cost to deliver proton therapy would be less if a Canadian facility were available.
  • Canadian doctors and patients eagerly await the day when a cancer patient can receive this advanced treatment without travelling out of country.
  • Having access to proton therapy would also allow Canadian researchers to collaborate globally in scientific studies.


Derek Tsang receives research grant funding from ACCESS (https://accessforkidscancer.ca), the Brain Tumour Foundation of Canada, and the US National Cancer Institute. Tsang also received travel funding from Mevion Medical Systems in 2022.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
Monday, February 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
RNA, Medical Subject Headings, Brain, Marketing, Agency, Health, INN, Risk, Stomach, Ependymoma, ATC, Medulloblastoma, Radiation, International, Blood, Language, DNA, Literature, Hodgkin lymphoma, Chemotherapy, Cancer, Skin cancer, Glioblastoma, Astrocytoma, Haematopoiesis, European Medicines Agency, Neoplasm, Transplant, Select, Cell, Patient, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 29, 2023
Phase, Conference, AACR, WRN, IDH, MTA, Medulloblastoma, Sarcoma, Research, American Society of Hematology, Phases of clinical research, Society, Therapy, MDS, Pharmacokinetics, Lymphoma, Ruxolitinib, ASH, BioNTech, Common, Incentive program, Syndrome, MEK, Exelixis, Patient, AML, PRMT5, Principal investigator, Pharmaceutical industry

Ryvu’s PRMT5 program and synthetic lethality platform were highlighted with preclinical data recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Key Points: 
  • Ryvu’s PRMT5 program and synthetic lethality platform were highlighted with preclinical data recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • KRAKOW, Poland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the third quarter of 2023 and provided a corporate update.
  • “The third quarter and the last months of 2023 proved to be an exceptionally productive period for our company,” said Pawel Przewięźlikowski, CEO of Ryvu Therapeutics.
  • Cash Position – On November 24, 2023, Ryvu Therapeutics held $64.5M in cash, cash equivalents, and bonds, compared to $23.2M at the end of 2022.

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 9, 2023
Cisplatin, Literacy, Food and Drug Administration, Neuroblastoma, FENC, Safety, COG, Food, GMT, Ototoxicity, Incidence, Risk, Patient, Medulloblastoma, FDA, Hepatoblastoma, Conference, Kool-Aid, Germ cell tumor, Survival, Hearing loss, RESEARCH, Osteosarcoma, TSX, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.
  • The management team will also host one-on-one investor meetings at the conferences.
  • Event: Jefferies London Healthcare Conference in London, UK
    Time: Company Presentation at 5:00 a.m.
  • It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Retrieved on: 
Monday, October 23, 2023
Medulloblastoma, Bone marrow, Plasma, AUC, Acute myeloid leukemia, Cmax, ESMO, Erythropoiesis, Principal investigator, Aes, PD, Congress, MD, Adenoid cystic carcinoma, CEST, Ruxolitinib, Cell, Data, Syndrome, All-comers track meet, Phase, SD, Risk, Webcast, Pancreatic cancer, Venetoclax, NPM1, WSE, ADCC, Safety, European Society for Medical Oncology, Patient, AML, Sarcoma, Pharmaceutical industry, Medical imaging, Dietary supplement

The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.

Key Points: 
  • The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.
  • The presented RVU120 development plan aligns with the budget outlined in Ryvu Development Plans for 2022-2024 and targets multi-billion-dollar market potential.
  • At the ESMO Congress 2023, Ryvu announced updated clinical Phase I data from Phase I/II study of RVU120 in relapsed/refractory metastatic advanced solid tumors.
  • Ryvu will host a webinar today (Monday, October 23) at 9:00 am CEST to discuss further RVU120 development plans.

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

Retrieved on: 
Thursday, October 12, 2023
Research, Medical Devices, Clinical Trials, Radiology, University, Health, Science, Education, Oncology, Other Science, Stanford University, GBM, Ependymoma, Bevacizumab, Survival, Stanford University School of Medicine, Medicine, Cancer, Patient, Temozolomide, Stanford School, TRIDENT, Meningioma, Pharmaceutical industry, Vaccine, Medulloblastoma

Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.
  • The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
  • “We look forward to collaborating with Stanford Medicine to establish a research framework for preclinical and clinical development of TTFields,” said Moshe Giladi, Ph.D., Novocure’s Chief Science Officer.
  • At present, Stanford Medicine is a site for four clinical studies of TTFields therapy.